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The non-receptor tyrosine kinase c-Src is an important mediator in several signaling
pathways related to neuroinflammation. Our previous study showed that cortical injection
of kainic acid (KA) promoted a transient increase in c-Src activity in reactive astrocytes
surrounding the neuronal lesion. As a cell-penetrating peptide based on connexin43
(Cx43), specifically TAT-Cx43266–283, inhibits Src activity, we investigated the effect of
TAT-Cx43266–283 on neuronal death promoted by cortical KA injections in adult mice. As
expected, KA promoted neuronal death, estimated by the reduction in NeuN-positive
cells and reactive gliosis, characterized by the increase in glial fibrillary acidic protein
(GFAP) expression. Interestingly, TAT-Cx43266–283 injected with KA diminished neuronal
death and reactive gliosis compared to KA or KA+TAT injections. In order to gain
insight into the neuroprotective mechanism, we used in vitro models. In primary cultured
neurons, TAT-Cx43266–283 did not prevent neuronal death promoted by KA, but when
neurons were grown on top of astrocytes, TAT-Cx43266–283 prevented neuronal death
promoted by KA. These observations demonstrate the participation of astrocytes in the
neuroprotective effect of TAT-Cx43266–283. Furthermore, the neuroprotective effect was
also present in non-contact co-cultures, suggesting the contribution of soluble factors
released by astrocytes. As glial hemichannel activity is associated with the release of
several factors, such as ATP and glutamate, that cause neuronal death, we explored
the participation of these channels on the neuroprotective effect of TAT-Cx43266–283. Our
results confirmed that inhibitors of ATP and NMDA receptors prevented neuronal death
in co-cultures treated with KA, suggesting the participation of astrocyte hemichannels
in neurotoxicity. Furthermore, TAT-Cx43266–283 reduced hemichannel activity promoted
by KA in neuron-astrocyte co-cultures as assessed by ethidium bromide (EtBr) uptake
assay. In fact, TAT-Cx43266–283 and dasatinib, a potent c-Src inhibitor, strongly reduced
the activation of astrocyte hemichannels. In conclusion, our results suggest that TAT-
Cx43266–283 exerts a neuroprotective effect through the reduction of hemichannel activity
likely mediated by c-Src in astrocytes. These data unveil a new role of c-Src in the
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regulation of Cx43-hemichannel activity that could be part of the mechanism by which
astroglial c-Src participates in neuroinflammation.
Keywords: connexin, c-Src, hemichannels, excitotoxicity, neuroinflammation, neuroprotection, neurons,
astrocytes
INTRODUCTION
Neuronal excitotoxicity mediated by glutamate receptors
contributes to a variety of disorders in the central nervous
system (CNS), including acute insults like ischemic stroke
or neurodegenerative diseases, such as Alzheimer’s disease,
Parkinson’s disease or Huntington’s chorea (Zhang and
Zhu, 2011; Lewerenz and Maher, 2015). The initial neuronal
excitotoxic damage causes reactive gliosis, an inflammatory
response characterized by the proliferation and activation of
microglia and astrocytes, which contributes to the outcome of
the neurodegenerative process. Excitotoxic neuronal death
is commonly induced experimentally in rodents by the
administration of kainic acid (KA), a potent agonist to the
AMPA/kainate class of glutamate receptors.
Our previous studies showed that after a cortical lesion
induced by a KA injection, astrocytes within the area depleted
in neurons reacted with an increase in glial fibrillary acidic
protein (GFAP) and a decrease in connexin43 (Cx43) expression
(Koulakoff et al., 2008), the main protein that forms gap junction
channels and hemichannels in astrocytes (Giaume et al., 2010,
2013). Furthermore, we found a transient increase in c-Src
activity in this region surrounding the neuronal lesion (Gangoso
et al., 2012).
c-Src, is a non-receptor tyrosine kinase very well-known
because of its oncogenic properties in many cancers. However,
c-Src also plays an important role in inflammatory signaling
(Byeon et al., 2012; Liu et al., 2014). Within the CNS, the
participation of c-Src signaling in neuroinflammation has
been well documented (Song et al., 2016), for instance mice
lacking c-Src show decreased infarct volumes after stroke (Paul
et al., 2001). This study elegantly demonstrates that c-Src
represents a key intermediate in the pathophysiology of cerebral
ischemia, where it appears to regulate neuronal damage by
influencing vascular endothelial growth factor-mediated vascular
permeability. Similarly, the inhibition of c-Src, through the
reduction of neuroinflammation, promotes a neuroprotective
effect in Parkinson’s disease and Alzheimer’s disease models
(Dhawan and Combs, 2012; Tai et al., 2013).
We have recently shown that Cx43, through the interaction
with c-Src and its endogenous inhibitors c-terminal Src kinase
(CSK) and phosphatase and tensin homolog (PTEN), inhibits
c-Src activity in astrocytes and glioma cells (Herrero-González
et al., 2010; González-Sánchez et al., 2016; Tabernero et al.,
2016). In fact, a cell-penetrating peptide based on this interacting
region, TAT-Cx43266–283, is sufficient to recruit c-Src, CSK
and PTEN and to inhibit c-Src activity in different types of
glioma cells (Gangoso et al., 2014; González-Sánchez et al., 2016;
Jaraíz-Rodríguez et al., 2017). As c-Src activity, an important
mediator in neuroinflammation, is increased after an excitotoxic
neuronal lesion (Gangoso et al., 2012), we presently investigated




C57BL6 mice were maintained in the animal facility of the
Collège de France (Paris). Animal experimentation was carried
out in accordance with the European Community Council
Directives (2010/63/UE) and care was taken to minimize their
suffering. The study with C57BL6 mice was approved by the
bioethics committee of the Collège de France (Paris). Albino
Wistar rats were obtained from the animal house of the
University of Salamanca (Spain) and were used according to local
and EU Ethical Committee guidelines. The study with Albino
Wistar rats was approved by the bioethics committee of the
University of Salamanca and Junta de Castilla y León (Spain).
Peptides
Synthetic peptides (>85% pure) were obtained from GenScript
(Piscataway, NJ, USA). YGRKKRRQRRR was used as the
TAT sequence, which is responsible for the cell penetration
of the peptides. The sequence of TAT-Cx43266–283 was
TAT-AYFNGCSSPTAPLSPMSP (Gangoso et al., 2014).
Kainic Acid Lesion and Peptide
Administration in Mice
Adult mice were subjected to intracerebral injection as previously
described (Koulakoff et al., 2008; Gangoso et al., 2012). Briefly,
mice were deeply anesthetized by intraperitoneal injection of
0.3 mL of 2% avertin and were then subjected to a low-pressure
injection of 1 nmol KA (Sigma-Aldrich, St. Louis, MO, USA) in
1 µL phosphate-buffered saline (PBS) in controls, 1 nmol KA
plus 1 nmol TAT in 1 µl PBS, or 1 nmol KA plus 1 nmol TAT-
Cx43266–283 in 1 µl PBS under stereotaxic guidance (coordinates:
−2.1 mm anteroposterior, 1.5 mm mediolateral and 0.6 mm
dorsoventral from Bregma) aiming the injection into the right
cerebral cortex. Animals were sacrificed by cervical dislocation at
7 days post-injection.
Quantification of the Extent of Neuronal
Lesions in Mice
Cryostat sections (20 µm) prepared as previously described
(Mei et al., 2010) were fixed for 30 min at room temperature
with 4% paraformaldehyde, washed in PBS and pre-incubated
for 1 h in PBS containing 0.2% gelatine and 0.2% Triton-
X100. Brain sections were incubated overnight at 4◦C
with rabbit polyclonal antibody anti-GFAP (1:1000, G9269;
Sigma) and mouse monoclonal anti-NeuN (1:500, MAB377;
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 December 2017 | Volume 10 | Article 418
Gangoso et al. Neuroprotective Effects of TAT-Cx43266–283
Merck Millipore, Madrid, Spain). After three washes with
PBS, sections were incubated for 2 h at room temperature
with their corresponding Alexa Fluor secondary antibodies
(1:2000; Life Technologies, Carlsbad, CA, USA). After several
washes, slices were mounted in Fluoromount (Southern
Biotechnologies, Birmingham, AL, USA) and examined with
an epifluorescence microscope (Eclipse E800; Nikon, Tokyo,
Japan).
For quantification, the whole area of the lesion was analyzed
using Fiji (Schindelin et al., 2012). Every 20 µm across the
entire lesion (1500 µm), the damaged area was drawn in each
slice with the freehand selection tool (Figure 1A). For drawing,
we followed as criteria a reduction in NeuN staining within
neurons compared with the contralateral region. The necrotic
tissue was included as part of the lesion (Figure 1B). Sometimes
the necrotic tissue was lost but that area was counted, assuming
it was damaged tissue. Although some slices where lost during
the sectioning process, all the conditions analyzed comprised at
least 80% of the lesion. The areas across the whole lesion were
plotted against their location using Prism software. Cavalieri’s
principle was used to estimate the volume of the lesion (Jelsing
et al., 2005). Briefly, the volume was estimated multiplying the
summatory of the areas, obtained as described previously, by the
distance between the sections analyzed along the rostro-caudal
axis.
Neuron and Astrocyte Cultures
Primary cultures were obtained as previously described
(Tabernero et al., 1993). For neuron cultures, rat fetuses at
17.5 days of gestation were delivered by rapid hysterectomy
after cervical dislocation of the mother. Postnatal 1-day
newborn rats were used to prepare astrocytes in culture.
Briefly, animals were decapitated and their brains immediately
excised. After removing the meninges and blood vessels, the
forebrains were placed in Earle’s balanced solution (EBS)
containing 20 µg/ml DNase and 0.3% (w/v) BSA. The
tissue was minced, washed, centrifuged and incubated in
0.025% trypsin (type III) and 60 µg/ml DNase I for 15 min
at 37◦C. Trypsinization was terminated by the addition of
Dulbecco’s Modified Eagle’s Medium (DMEM) containing
10% fetal bovine serum (FCS; Gibco, Life Technologies). The
tissue was then dissociated by gently passing it eight times
through a siliconized Pasteur pipette, and the supernatant
cell suspension was recovered. This operation was repeated
and the resulting cell suspension was centrifuged. The cells
were then resuspended in DMEM containing 10% FCS
and plated on Petri dishes coated with 10 µg/ml poly-L-
lysine at a density of 105 cells/cm2. Cells were maintained at
37◦C and 5% CO2. One day after plating, 10 µM cytosine
arabinoside was added to avoid glial cell proliferation on
neuronal cultures.
Neuron-Astrocyte Co-cultures
For neuron-astrocyte co-cultures, the cell suspension obtained
for neuron culture was plated at a density of 3.75 × 104
cells/cm2 on confluent 21 days in vitro (DIV) astrocytes. These
co-cultures were maintained at 37◦C and 5% CO2 in DMEM +
10% FCS for 7 days and then different treatments were applied
for 8 h.
For non-contact neuron-astrocyte co-cultures, the cell
suspension obtained for neuron culture was plated at a density
of 105 cells/cm2 in 12-well plates coated with 10 µg/ml poly-
L-lysine. Cells were maintained at 37◦C and 5% CO2 and
1 day after plating, cytosine arabinoside was added to avoid
glial cell proliferation. Eighteen DIV astrocytes were plated in
500 µL DMEM + 10% FCS on inserts containing polyethylene
terephthalate filters with 1-µm pores (Merck Millipore) at 105
cells/cm2, whereas 1 ml DMEM + 10% FCS was added to the
lower well. After 3 days, the medium of the astrocytes was
changed and the inserts were placed on top of 4 DIV neurons
with 25% of the medium changed. These non-contact co-cultures
were maintained at 37◦C and 5% CO2 in DMEM + 10% FCS in
the presence of the different treatments for 3 days.
Cell Treatments
All treatments were added to the culturemedium andmaintained
at 37◦C for the indicated times. The treatments were as follows:
50 µM TAT, 50 µM TAT-Cx43266–283, 100 µM KA, 10 µg/ml
lipopolysaccharide (LPS; Sigma), 200 µM carbenoxolone (CBX;
hemichannel inhibitor, Sigma), 1 µM dasatinib (c-Src inhibitor;
Selleck Chemicals, Munich, Germany), dimethyl sulfoxide
(vehicle for dasatinib; 1 µl/ml), 20 µM 3-(2-carboxypiperazin-
4-yl)propyl-1-phosphonic acid (CPP; NMDA receptor blocker),
200 µM Adenosine 5′-triphosphate, periodate oxidized sodium
salt (oATP; P2X receptor blocker, Sigma) and 100 µM Brilliant
Blue G (BBG; P2X7 receptor blocker, Sigma).
Immunocytochemistry
Cells were fixed with 4% (w/v) paraformaldehyde in PBS
for 20 min and blocked for 30 min in antibody diluting
solution (PBS containing 10% FCS, 0.1 M lysine and 0.02%
sodium azide). Cells were then incubated overnight at 4◦C
with mouse anti-NeuN (1:100) and for 2 h with the secondary
antibody anti-mouse labeled with Alexa Fluor 488 (A11029;
Life Technologies) all prepared in antibody diluting solution
containing 0.1% Triton-X100. Nuclei were stained with 4′,6′-
diamidino-2-phenylindole (DAPI; 1.25 µg/ml; Invitrogen) for
10 min. Cells were then mounted using the Slowfade Gold
Antifade Kit (ThermoFisher) and analyzed on a Nikon inverted
fluorescence microscope connected to a digital video camera
(DC100; Leica, Wetzlar, Germany). Negative controls carried out
by omission of the primary antibodies resulted in absence of
staining in all cases. At least six photomicrographs were taken
from each plate. The number of nuclei (DAPI staining) and
NeuN-positive cells were counted with ImageJ (NIH, Bethesda,
MD, USA) on 8-bit images. The percentage of NeuN-positive
cells was calculated from the total number of cells (DAPI
staining).
MTT Assay
Cells cultured at 37◦C were incubated in the dark for
75 min with culture medium containing 0.5 mg/ml MTT
(Sigma). The medium was then removed, and the cells were
incubated for 10 min in the dark with dimethyl sulfoxide
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FIGURE 1 | Effect of TAT-connexin43 (Cx43)266–283 on NeuN and glial fibrillary acidic protein (GFAP) expression in adult mouse brain after kainic acid (KA) injection.
(A) Schematic of the experimental strategy used to analyze neuronal injury promoted by 1 nmol/µl KA injection. (B) Expression of NeuN and GFAP in the cortex,
7 days after KA injection. Representative photomicrographs from the same field at the level of the lesioned area delimited by the dashed red line. (C) Quantification of
neuronal death area along the rostrocaudal axis. Representative photomicrographs of GFAP (D) and NeuN (E) immunohistochemical staining in brain sections at the
level of the lesioned area, 7 days after the injection of 1 nmol/µl KA + 1 nmol/µl TAT or 1 nmol/µl KA + 1 nmol/µl TAT-Cx43266–283. Higher magnification
photomicrographs showing the decrease in NeuN-positive cells after the injection of KA+TAT compared to KA+TAT-Cx43266–283. Bar, 250 µm.
with mild shaking. Finally, the absorbance was measured at a
wavelength of 570 nm using a microplate reader (Appliskan
2001; Thermo Electron Corporation, Thermo Scientific, Madrid,
Spain).
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Ethidium Bromide Uptake Analyses in Cell
Cultures
Cultured cells were incubated with 5 µM ethidium bromide
(EtBr) in HEPES-buffered salt solution (140 mM NaCl, 5.4 mM
KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 5 mM
HEPES; pH 7.4) for 10min. Cells were thenwashedwith the same
buffer, fixed with 4% paraformaldehyde in PBS and analyzed on
a Nikon inverted fluorescence microscope connected to a digital
video camera (Leica DC100). The EtBr fluorescence intensity
within the nucleus was measured with the ImageJ software and
the average of data from six images from different fields in the
same culture was calculated to obtain the final measurement of
dye uptake in each culture.
Assessment of Gap Junctional Intercellular
Communication
Gap junction permeability was determined by the scrape-
loading/dye transfer technique as previously described (Herrero-
González et al., 2010). Scrape-loading was performed by scraping
the cell layer with a broken razor blade in a Ca2+-free ionic
solution containing Lucifer yellow (LY; 1 mg/ml). LY is a
low molecular weight (457 Da) fluorescent dye that can pass
through the gap junctions of loaded cells to their neighbors.
After 2 min, the dye solution was removed and the cells
were carefully washed. Subsequently, 8 min after scraping,
fluorescence photomicrographs were captured with a digital
video camera (Leica DC100) connected to an inverted fluorescent
microscope equipped with the appropriate filters (Diaphot,
Nikon). At least six photomicrographs of the center of the dish
were taken and the number of fluorescent cells per field were
counted.
Statistical Analysis
Results are expressed as the mean ± SEM of at least three
independent experiments. Statistical analyses were carried out
in Sigma Plot 11 (Systat Software) using an analysis of variance
(one-way ANOVA), followed by the Holm-Sidak method for
multiple comparisons at a significant level of p < 0.05.
RESULTS
TAT-Cx43266–283 Exerts Neuroprotective
Effects in in Vivo KA-Induced Cortical
Lesions
Following the method previously described (Koulakoff et al.,
2008), KA was cortically injected and after 7 days, brains were
dissected, fixed and 20-µm frontal sections were cut along
1500 µm to cover the entire lesion (Figure 1A). Neuronal death
was estimated by measuring the area in which neurons contain a
reduced NeuN intensity when compared to contralateral region
(Figure 1B), as described in ‘‘Materials and Methods’’ section.
In agreement with previous results (Koulakoff et al., 2008), KA
promoted neuronal death and reactive gliosis, characterized by
the increase in GFAP expression (Figure 1B). Figure 1C shows
neuronal death areas along the rostrocaudal axis found 7 days
after KA injection.
Next, we analyzed the effect of TAT-Cx43266–283 on neuronal
death promoted by KA using TAT penetrating peptide as a
control. TAT-Cx43266–283 was injected with KA and its effect
was compared with KA or KA+TAT. Our results showed
that TAT-Cx43266–283 diminished reactive gliosis as judged by
GFAP staining (Figure 1D). More importantly, TAT-Cx43266–283
prevented the reduction in NeuN-positive cells promoted by KA
(Figure 1E).
Indeed, when the neuronal death area was estimated along
the rostrocaudal axis (Figure 2), there was a strong reduction in
neuronal death in animals injected with KA+TAT-Cx43266–283
(Figure 2C1) compared to KA (Figure 2A1) or KA+TAT
(Figure 2B1). Quantification of neuronal death areas along
the rostrocaudal axis showed a reduction in the height and
length of the curves in mice treated with KA+TAT-Cx43266–283
(Figure 2C2) compared to KA (Figure 2A2) or KA+TAT
(Figure 2B2). The area under these curves was calculated, using
Cavalieri’s principle (described in ‘‘Materials and Methods’’
section) as an estimation of the volume of these lesions
(Figure 2D). These results confirmed that TAT-Cx43266–283
strongly reduced the extent of neuronal death promoted by KA
injection (Figure 2D).
Astrocytes Are Involved in the
Neuroprotective Effect of TAT-Cx43266–283
In order to gain insight into the neuroprotective mechanism
of TAT-Cx43266–283 we used cell cultures to address the
contribution of each type of cell to this process. First, the
effect of KA and TAT-Cx43266–283 in neurons from primary
cultures was analyzed. Surprisingly, TAT-Cx43266–283 did not
protect against neuronal death promoted by KA in these
cultures (Figure 3), suggesting the participation of a glial cells
partnership in the neuroprotective effect of TAT-Cx43266–283.
Indeed, when neurons were grown on top of astrocyte cultures,
TAT-Cx43266–283 prevented neuronal death promoted by KA
(Figure 4). The number of NeuN-positive cells decreased in
neuron-astrocyte co-cultures in the presence of KA (Figure 4A
vs. Figure 4B). However, when KA was added together with
TAT-Cx43266–283 (Figure 4D) the number of NeuN-positive cells
was not reduced when compared with the control (Figure 4A).
Quantification of this data (Figure 4E) confirmed the preventive
effect of TAT-Cx43266–283 on the reduction of NeuN-positive
cells promoted by KA treatment in neuron-astrocyte co-cultures.
It should be mentioned that TAT-Cx43266–283 did not affect
NeuN staining in neuron-astrocyte co-cultures in the absence
of KA (Supplementary Figure S1). In agreement with previous
studies (Meloni et al., 2014), TAT also showed a slight
neuroprotective effect, although it was lower to that found with
TAT-Cx43266–283, suggesting that the region 266–283 in Cx43 has
a neuroprotective effect.
To address whether a change in the production of diffusible
molecule was involved in the neuroprotective effect, non-contact
neuron-astrocyte co-cultures were used. Astrocytes cultured
within inserts were placed into wells containing neuronal
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FIGURE 2 | Effect of TAT-Cx43266–283 on the extent of neuronal death in adult mouse brain cortex after KA injection. Representative photomicrographs of NeuN
immunohistochemical staining in brain sections at the level of the lesioned area, 7 days after 1 nmol/µl KA injection (A1), KA+TAT (B1) or KA+TAT-Cx43266–283 (C1).
The lesioned area was delimited by a dashed red line and quantified along the rostrocaudal axis, 7 days after KA injection (A2), KA+TAT (B2) or KA+TAT-Cx43266–283
(C2). The areas of at least 50 sections per animal were quantified. The results from three independent experiments were plotted on each graph. (D) Quantification of
neuronal death volume (means ± SEM n = 3). ∗p < 0.05 ANOVA post-test (Holm-Sidak method for multiple comparisons). Bar, 250 µm.
cultures, as illustrated in Figure 5A. After different treatments,
astrocyte inserts were removed and neuronal viability was
estimated by MTT viability assays as described in ‘‘Materials
and Methods’’ section. In parallel, neurons were subjected to the
same treatments in the absence of astrocyte inserts. Consistent
with the images shown in Figure 3, in the absence of glial
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FIGURE 3 | Effect of TAT-Cx43266–283 on neuronal death promoted by KA in
cultured neurons. Representative phase-contrast photomicrographs showing
that 100 µM KA induced neurotoxicity in cultured neurons in the presence or
absence of 50 µM TAT or TAT-Cx43266–283 for 72 h. Bar, 20 µm.
cells TAT-Cx43266–283 did not significantly modify neuronal
death promoted by KA (Figure 5B). However, in the presence
of inserts containing astrocytes, TAT-Cx43266–283 prevented
neuronal death promoted by KA (Figure 5B), suggesting that
soluble factors released by astrocytes are contributing to this
effect.
Astrocyte Hemichannels Contribute to
KA-Induced Neurotoxicity
It has been extensively documented that astrocyte hemichannels
when activated release several factors, such as glutamate and
ATP that cause neuronal death (Orellana et al., 2011a).
Therefore, we explored the participation of these channels
in KA-induced neurotoxicity. Adding 200 µM oATP (P2X
receptor blocker), 100 µM BBG (P2X7 receptor blocker) or
20 µM CPP (NMDA receptor blocker) during KA incubation
prevented the reduction in NeuN-positive cells caused by KA
in neuron-astrocyte co-cultures (Figure 6). Together these
data confirmed that inhibitors of ATP- and NMDA-receptors
prevented neuronal death in co-cultures treated with KA,
suggesting the participation of glutamate and ATP release
FIGURE 4 | Effect of TAT-Cx43266–283 on neuronal death promoted by KA in
neuron-astrocyte co-cultures. Representative photomicrographs of NeuN
immunocytochemistry (green) and 4′,6′-diamidino-2-phenylindole (DAPI)
nuclear staining (blue) in control neuron-astrocyte co-cultures (A) or
co-cultures treated with 100 µM KA (B), 100 µM KA + 50 µM TAT (C) or
100 µM KA + 50 µM TAT-Cx43266–283 (D) for 8 h. (E) Bar chart showing the
ratio of NeuN-positive cells against the total number of cells stained with DAPI
per field. The results are the means ± SEM (n = 4) and are expressed as
percentages of the control (0KA). ∗∗∗p < 0.001 ANOVA (post-test
Holm-Sidak). Bar, 20 µm.
associated with astrocyte hemichannel activity in this neurotoxic
process.
TAT-Cx43266–283 Inhibits Astrocyte
Hemichannel Activity Through c-Src
Because astrocyte hemichannels appeared to be involved in
KA-mediated neuronal death (Figure 6), we hypothesized that
TAT-Cx43266–283 could prevent hemichannel activation with the
subsequent neuroprotective effect. To address this point, first
we analyzed the effect of TAT-Cx43266–283 on glial hemichannel
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FIGURE 5 | Effect of TAT-Cx43266–283 on neuronal death promoted by KA in
non-contact neuron-astrocyte co-cultures. (A) Schematic of the non-contact
neuron-astrocyte co-culture system used. (B) Neurons were plated alone or in
co-culture with astrocytes. After incubation in the absence (control) or
presence of 100 µM KA, 100 µM of KA + 50 µM TAT or 100 µM KA + 50 µM
TAT-Cx43266–283 for 72 h, the neuronal viability was analyzed by MTT. The
results are expressed as the percentages of the absorbance found in the
control and are the mean ± SEM (n = 3). ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05;
ANOVA (post-test Holm-Sidak).
activity by EtBr uptake (Figure 7). Under resting conditions,
glial hemichannel activity is negligible (Figure 7B, dotted line),
therefore astrocytes were exposed to LPS for 24 h to increase
hemichannel activity (Retamal et al., 2007; Orellana et al.,
2011a). As shown in Figure 7A, LPS-treated astrocytes showed
a strong uptake of the hemichannel permeable tracer. This
effect was suppressed by CBX, a hemichannel inhibitor, applied
in the presence of LPS, 15 min before and during the EtBr
uptake (Figures 7A,B), demonstrating that EtBr uptake occurred
through hemichannels. Interestingly, TAT-Cx43266–283 applied
in the same way, i.e., in the presence of LPS, 15 min before
and during the EtBr uptake, strongly reduced the activation of
hemichannels promoted by LPS (Figures 7A,B). Since TAT-
Cx43266–283 is an inhibitor of c-Src (Gangoso et al., 2014),
which is an important mediator of neuroinflammation (Paul
et al., 2001; Tai et al., 2013), we investigated the effect of
dasatinib, a potent inhibitor of Src, on hemichannel activity.
Dasatinib inhibited astrocyte hemichannel activity promoted by
LPS (Figure 7B), revealing a role of c-Src in the regulation
of hemichannel activity. Furthermore, the results obtained
with dasatinib were very similar to those obtained with TAT-
Cx43266–283 suggesting that TAT-Cx43266–283, by inhibiting
c-Src, reduced hemichannel activity in astrocytes. We also
analyzed the effect of TAT-Cx43266–283 on the communication
through gap junctions in astrocytes (Figure 7C). The scrape
loading assay showed that TAT-Cx43266–283 did not significantly
modify gap junction intercellular communication between
astrocytes.
To test the involvement of hemichannel activity on the
neuroprotective effect of TAT-Cx43266–283 in KA-induced
neurotoxicity, EtBr uptake was analyzed in neuron-astrocyte
co-cultures treated with KA. Figures 7D,E show that KA
strongly increased hemichannel activity in these co-cultures.
Interestingly, TAT-Cx43266–283 applied in the presence of KA
FIGURE 6 | Effect of glutamate and ATP on neuronal death promoted by KA
in neuron-astrocyte co-cultures. Representative photomicrographs of NeuN
immunocytochemistry (green) and DAPI nuclear staining (blue) in
neuron-astrocyte co-cultures treated with 100 µM KA (A), 100 µM KA +
200 µM oATP (P2X receptor blocker; B), 100 µM KA + 100 µM Brilliant Blue
G (BBG; P2X7 receptor blocker; C) or 100 µM KA + 20 µM CPP (NMDA
receptor blocker; D) for 8 h. (E) Bar chart showing the ratio of NeuN-positive
cells against the total number of cells stained with DAPI per field. The results
are the means ± SEM (n = 3) and are expressed as percentages of the control
(0KA). ∗p < 0.05 vs. control (0 KA), ∗∗∗p < 0.001 vs. KA; ANOVA (post-test
Holm-Sidak). Bar, 20 µm.
strongly inhibited hemichannel activity (Figures 7D,E). In fact,
the inhibition promoted by TAT-Cx43266–283 was similar to that
promoted by CBX, a hemichannel inhibitor, or by dasatinib, a
c-Src inhibitor (Figures 7D,E). These data suggest that TAT-
Cx43266–283 by inhibiting c-Src activity prevented hemichannel
activity promoted by KA in neuron-astrocyte co-culture.
We then investigated whether KA, per se, affected
astrocyte hemichannel activity. Figure 7B shows that KA
did not activate hemichannels in astrocytes. However,
when astrocytes were exposed to conditioned medium
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FIGURE 7 | Effect of TAT-Cx43266–283 on astrocyte hemichannel activity and gap junctional intercellular communication (GJIC) in astrocyte cultures and in
neuron-astrocyte co-cultures. (A,B) Astrocyte cultures were incubated with 10 µg/ml lipopolysaccharide (LPS) for 24 h or with 100 µM KA or conditioned medium
from KA-treated neuron-astrocyte co-cultures (CM) for 8 h. Then, 5 µM ethidium bromide (EtBr) was added for 10 min. Two-hundred micromolar Carbenoxolone
(CBX), 50 µM TAT-Cx43266–283, 1 µM dasatinib and 1 µl/ml dimethyl sulfoxide were applied in the presence of LPS, 15 min before and during EtBr uptake.
(A) Representative photomicrographs showing EtBr uptake in astrocytes after LPS treatment and the inhibition promoted by CBX and TAT-Cx43266–283.
(B) Quantification of EtBr uptake intensity in arbitrary units (AU). Dotted line represents the basal level of EtBr fluorescence found in untreated astrocytes. The results
are the means ± SEM (n = 3; at least 300 cells were counted per condition). ∗∗p < 0.01, ANOVA (post-test Holm-Sidak). (C) Astrocyte cultures were incubated in the
absence or presence of 50 µM TAT-Cx43266–283 24 h before and during the scrape-loading experiment. Photomicrographs obtained after Lucifer yellow (LY) scrape
loading and quantification of the number of fluorescent cells per field. The results are the means ± SEM (n = 3). (D,E) Neuron-astrocyte co-cultures were incubated
with 100 µM KA for 8 h and then 5 µM EtBr was added for 10 min. Two-hundred micromolar CBX, 50 µM TAT-Cx43266–283 or 1 µM dasatinib were applied in the
presence of KA, 15 min before and during EtBr uptake. (D) Representative photomicrographs showing EtBr uptake in neuron-astrocyte co-cultures after KA
treatment and the inhibition promoted by CBX and TAT-Cx43266–283. (E) Quantification of EtBr uptake intensity in AU. The results are the means ± SEM (n = 3; at
least 300 cells were counted per condition). ∗∗∗p < 0.001 ANOVA (post-test Holm-Sidak). Bar, 50 µm.
from KA-treated neuron-astrocyte co-cultures, the activity
of astrocyte hemichannels strongly increased (Figure 7B).
These results confirm that some factors released by damaged
neurons, but not KA, activate astrocyte hemichannels.
Altogether, these data suggest that TAT-Cx43266–283, by
inhibiting c-Src, prevents the activation of hemichannels
caused by factors released by KA-damaged neurons
(Figure 8).
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FIGURE 8 | Proposed mechanism of TAT-Cx43266–283 neuroprotective effect. (1) KA induces neuronal death by excitotoxicity. (2) This injury promotes the release of
proinflammatory molecules that cause the activation of c-Src in astrocytes. (3) c-Src, among other effects, can activate astrocyte hemichannels, causing the release
of some factors, such as ATP and glutamate. (4) ATP and glutamate increase the extent of neuronal death. (5) TAT-Cx43266–283 inhibits c-Src activity and
consequently glial hemichannel activity with the subsequent neuroprotective effect.
DISCUSSION
Our previous studies reported that a cortical injection of KA
promoted a transient increase in c-Src activity in the region
surrounding the neuronal lesion (Gangoso et al., 2012). c-Src is
an important mediator in several signaling pathways related to
neuroinflammation (Paul et al., 2001; Tai et al., 2013). In this
study, we revealed that TAT-Cx43266–283, a Cx43mimetic peptide
that inhibits c-Src activity (Gangoso et al., 2014; González-
Sánchez et al., 2016; Jaraíz-Rodríguez et al., 2017), reduces the
extent of neuronal death promoted by KA.
Intriguingly, we show here that the neuroprotective effect of
TAT-Cx43266–283 in KA-injured neurons requires the presence
of astrocytes. Clearly, the initial neuronal injury promoted
by KA is due to excitotoxicity. As a potent agonist for
the AMPA/kainate class of glutamate receptor, KA increases
the production of reactive oxygen species, mitochondrial
dysfunction and apoptosis in neurons (Wang et al., 2005).
Similarly to other neuronal injuries, this primary tissue damage
induces subsequent neurotoxic factor release, resulting in the
activation of microglia cells and astrocytes that, although initially
exert a neuroprotective effect, in the long term contributes to
the delayed neuronal death (Hong et al., 2010; Zhang and Zhu,
2011). Although further research is required, it could be proposed
that TAT-Cx43266–283, by inhibiting c-Src, interferes with the
neuroinflammatory response evoked by activated astrocytes
after KA-induced neuronal death. In agreement with this, KA
promotes a transient increase in c-Src activity in activated
astrocytes surrounding KA-injured neurons (Gangoso et al.,
2012). Moreover, the present study shows that the inhibitor of
c-Src, TAT-Cx43266–283, reduces the activation of astrocytes that
follows KA lesion.
Astrocytes are known to represent the brain cell population
that expresses the higher among of connexins forming
hemichannels. Moreover, increasing evidence suggests that
inflammation-induced astrocyte hemichannel activation plays
a critical role in neuronal death (Bennett et al., 2012;
Ishii et al., 2013; Yi et al., 2016; Belousov et al., 2017;
Gajardo-Gómez et al., 2017). Thus, astrocyte hemichannels
in neuron-astrocyte co-cultures participate in NMDA-induced
neurotoxicity (Froger et al., 2010). The activation of astrocyte
hemichannels releases ATP and glutamate that contribute to
neuronal death (Orellana et al., 2011a; Bennett et al., 2012).
Although our results did not demonstrate that the release
of ATP and glutamate occurs directly from hemichannels,
because it was not under the scope of this study, they showed
a neurotoxic effect of ATP and glutamate that takes place
when astrocyte hemichannels are opened. Indeed, according to
our results, ATP and glutamate participate in neuronal death
promoted by KA in neuron-astrocyte co-culture, suggesting
the participation of astrocyte hemichannels in the neurotoxic
effect caused by KA. In agreement with this, the results
presented in this study showed that some factors released
by damaged neurons promoted the activation of astrocyte
hemichannels and neuronal death. Interestingly, this effect
was impaired by TAT-Cx43266–283, which inhibited astrocyte
hemichannel activity. The astrocyte hemichannel activation
appears to be mediated by c-Src, first because TAT-Cx43266–283
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has been reported to be an important inhibitor of c-Src
(Gangoso et al., 2014; González-Sánchez et al., 2016; Jaraíz-
Rodríguez et al., 2017) and also because other inhibitors
of c-Src, such as dasatinib, inhibited astrocyte hemichannel
activity.
Neuronal injury causes the release of several
pro-inflammatory cytokines such as TNF-alpha, IL-1or IL-6
(Feuerstein et al., 1994) that can activate c-Src (Yu et al., 2007;
Byeon et al., 2012; Liu et al., 2014; Song et al., 2016) and astrocyte
hemichannels (Froger et al., 2010). In fact, c-Src activation and
glial hemichannel activity are common events in several CNS
diseases, suggesting a link between them. Thus, the deleterious
contribution of c-Src activity to neurodegeneration have been
extensively documented in models of Parkinson’s disease (Tai
et al., 2013; Wang et al., 2016), Alzheimer’s disease (Dhawan
and Combs, 2012; Kaufman et al., 2015) and stroke (Paul et al.,
2001). Similarly, astrocytes open their Cx43 hemichannels in
Parkinson’s disease (Rufer et al., 1996; Kawasaki et al., 2009)
Alzheimer’s disease (Orellana et al., 2011b; Takeuchi et al.,
2011; Yi et al., 2016) and ischemia (Contreras et al., 2002;
Retamal et al., 2006). We found that c-Src inhibitors reduce
astrocyte hemichannel activity promoted by LPS or by damaged
neurons, suggesting that c-Src activity increases astrocyte
hemichannel activity. To our knowledge, there is no evidence
indicating that c-Src directly opens Cx43 hemichannels. c-Src
binds to the SH3 domain binding motif of Cx43 and then
phosphorylates tyrosines 265 and 247. As a consequence, gap
junctional intercellular communication (GJIC) is reduced, and
Cx43 turnover is initiated (Kanemitsu et al., 1997; Giepmans
et al., 2001; Sorgen et al., 2004). Although other possibilities
cannot be ruled out, these changes in Cx43 conformation and/or
location might be responsible for the increase in hemichannel
activity. Consistent with this, pioneer studies on Cx43 mimetic
peptides showed that the sequence 271–287 injected into
Xenopus oocytes prevented the inhibition of Cx43 gap junction
channels promoted by intracellular acidification (Calero et al.,
1998). Intracellular acidification increases c-Src activity (Yamaji
et al., 1997) and reduces gap junctional communication (Li et al.,
2005), suggesting a link between both processes (Lau, 2005).
Therefore, we speculated that the sequence 271–287, similarly
to TAT-Cx43266–283, could inhibit c-Src activity by recruiting
PTEN and CSK (González-Sánchez et al., 2016; Jaraíz-Rodríguez
et al., 2017) interfering with the effects of c-Src on Cx43-channel
properties.
Taken together, these results allow us to propose that
astrocyte hemichannel activity is increased after KA-neuronal
injury and that TAT-Cx43266–283, by inhibiting c-Src, among
other effects reduces astrocyte hemichannel activity with the
subsequent neuroprotective effect (Figure 8). Furthermore, it
should be mentioned that TAT-peptides can be delivered in vivo
in mice, and display penetration into the brain parenchyma
(Abudara et al., 2014; Stalmans et al., 2015), which increase
the interest of TAT-Cx43266–283 for the development of new
therapies to reduce excitotoxic-mediated neurodegeneration.
Additionally, the results obtained with this Cx43mimetic peptide
may provide some clues about the role played by the changes
in Cx43 expression found in astrocytes under pathological
conditions (Giaume et al., 2010). In this sense, in addition
to affect Cx43 channel functions, changes in Cx43 expression
can modulate c-Src activity. Thus, down-regulation of Cx43 in
astrocytes increases c-Src activity (Gangoso et al., 2012; Valle-
Casuso et al., 2012). Conversely, if TAT-Cx43266–283 mimics the
effect of the up-regulation of Cx43, the increase in astrocyte
Cx43 expression would reduce c-Src activity with the subsequent
reduction in hemichannel activity and neuroprotective effect.
Finally, this study opens the interesting possibility that glial
hemichannels could be involved in the neuroinflammatory
response mediated by c-Src in major CNS diseases like
Parkinson’s disease, Alzheimer’s disease or stroke (Paul et al.,
2001; Dhawan and Combs, 2012; Tai et al., 2013; Kaufman et al.,
2015; Wang et al., 2016).
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